Key stats
About CCB CSI Brand Name Drug Industry Exchange Traded Fund Units
Home page
Inception date
Mar 11, 2021
Structure
Open-Ended Fund
Replication method
Physical
Dividend treatment
Distributes
ISIN
CNE100004GD8
Tightly track the target index, and pursue the minimization of tracking deviation and tracking err. Under normal market conditions, the absolute value of the Fund's daily average tracking deviation should not exceed 0.2%, and the annual tracking err should not exceed 2%.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks97.47%
Health Technology96.90%
Commercial Services0.57%
Bonds, Cash & Other2.53%
Cash2.53%
Stock breakdown by region
Asia97.89%
Europe2.11%
North America0.00%
Latin America0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
159835 invests in stocks. The fund's major sectors are Health Technology, with 96.90% stocks, and Commercial Services, with 0.57% of the basket. The assets are mostly located in the Asia region.
159835 top holdings are WuXi AppTec Co., Ltd. Class A and Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A, occupying 9.88% and 9.84% of the portfolio correspondingly.
No, 159835 doesn't pay dividends to its holders.
159835 shares are issued by CCB Principal Asset Management Co., Ltd. under the brand CCB. The ETF was launched on Mar 11, 2021, and its management style is Passive.
159835 expense ratio is 0.60% meaning you'd have to pay 0.60% of your investment to help manage the fund.
159835 follows the CSI Innovative Drug Industry Index - CNY - Benchmark TR Gross. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
159835 invests in stocks.